Sugimoto T, Hayakawa H, Osada H, Yamazaki N, Mori H, Yasuda H, Sakamoto A
J Cardiovasc Pharmacol. 1986;8 Suppl 11:S171-4. doi: 10.1097/00005344-198511001-00031.
The effectiveness and safety of bisoprolol, a newly developed beta-adrenergic blocking drug, in the treatment of arrhythmias were evaluated in 17 patients with premature ventricular contraction (PVC), 8 with premature atrial contraction (PAC) and 7 with sinus tachycardia. More than 50% reduction of the PVC frequency was observed in 7 out of 16 patients. PVC was reduced in 2 out of 5 patients at a daily dose of 2.5 mg. The PAC frequency was decreased in 50% of the patients, and sinus tachycardia was improved in all 7 patients. Adverse reactions were observed in 8 of 32 patients. This preliminary study suggests that the antiarrhythmic effects of bisoprolol could be assessed starting at a daily dose of 2.5 mg to determine its optimal effective dose in Japanese patients.
对17例室性早搏（PVC）患者、8例房性早搏（PAC）患者和7例窦性心动过速患者评估了新开发的β-肾上腺素能阻滞剂比索洛尔治疗心律失常的有效性和安全性。16例患者中有7例观察到PVC频率降低超过50%。5例患者中2例在每日剂量2.5mg时PVC减少。50%的患者PAC频率降低，所有7例窦性心动过速患者均有改善。32例患者中有8例观察到不良反应。这项初步研究表明，比索洛尔的抗心律失常作用可从每日剂量2.5mg开始评估，以确定其在日本患者中的最佳有效剂量。
